COUNTERFEITING OF MEDICINAL PRODUCTS AND THREATS ASSOCIATED WITH THEIR TAKING
DOI:
https://doi.org/10.56782/pps.19Keywords:
counterfeit medicine, pharmaceutical crime, quality of medicinal productsAbstract
Currently, counterfeiting of medicinal products poses a threat to human health and life. This phenomenon occurs in many countries on all continents. World Health Organization presents data that the most commonly counterfeit of medicinal drugs are antimalarial drugs, antibiotics, PDE5 inhibitors, slimming drugs and anabolic steroids. The threat to health and life associated with the use of counterfeit medicinal products is serious. The use of such products makes impossible to provide safe and effective therapy, and also causes the occurrence of serious side effects. Patients using counterfeit drugs often have to be hospitalized. It negatively affects the country's economic situation. The falsification of medicinal products violates the intellectual property of copyright, trademarks and patents.
Downloads
References
WHO, Global Surveillance and Monitoring System for substandard and falsified medical products Reports and Executive summary Internet: https://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/.
WHO, 1 in 10 medical products in developing countries is substandard or falsified, Internet: https://www.who.int/en/news-room/detail/28-11-2017-1-in-10-medical-products-in-developing-countries-issubstandard-or-falsified.
Główny Inspektorat Farmaceutyczny, Miejsca dystrybucji sfałszowanych leków, Internet: https://www.gif.gov.pl/pl/ nadzor/sfalszowane-produkty-le/informacje-ogolne/miejscadystrybucji-sfa/480,Miejsca-dystrybucji-sfalszowanych-lekow.html.
Degardin K, Roggo Y, Margot P. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal. 2014, 87, 167-175. DOI: https://doi.org/10.1016/j.jpba.2013.01.009
Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med. 2017, 47(9), 1869-1883. DOI: https://doi.org/10.1007/s40279-017-0709-z
Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017, 135(21), 1991-2002. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026945
WHO, Growing threat from counterfeit medicines, Internet: https://www.who.int/bulletin/volumes/88/4/10-020410/en/.
Art. 2. pkt 38a, Ustawa z dnia 6 września 2001 r. - Prawo farmaceutyczne, Dz.U.2019.0.499.
WHO, Guidelines for the development of measures to combat counterfeit medicines, Geneva 1999, Internet: https://www.who.int/medicines/publications/counterfeitguidelines/en/.
WHO, Definitions of Substandard and Falsified (SF) Medical Products, Geneva, Internet: https://www.who.int/medicines/regulation/ssffc/definitions/en/.
Mackey TK, Cuomo R, Guerra C, Liang BA. After counterfeit Avastin(R)--what have we learned and what can be done? Nat Rev Clin Oncol. 2015, 12(5), 302-308. DOI: https://doi.org/10.1038/nrclinonc.2015.35
Nayyar GML, Breman JG, Mackey TK, Clark JP, Hajjou M, Littrell M, Herrington JE. Falsified and Substandard Drugs: Stopping the Pandemic. Am J Trop Med Hyg. 2019, 100(5), 1058-1065. DOI: https://doi.org/10.4269/ajtmh.18-0981
Główny Inspektorat Farmaceutyczny, Sukces operacji PANGEA liczony w milionach dolarów, 2018 Internet: https://www.gif.gov.pl/pl/aktualnosci/1333,Sukces-operacjiPANGEA-liczony-w-milionach-dolarow.html.
Dyrektywa Parlamentu Europejskiego i Rady 2011/62/UE z dnia 8 czerwca 2011r. zmieniająca dyrektywę 2001/83/WE w sprawie wspólnotowego kodeksu odnoszącego się do produktów leczniczych stosowanych u ludzi - w zakresie zapobiegania wprowadzeniu sfałszowanych produktów leczniczych do legalnego łańcucha dystrybucji, Dz.U. UE L, 174/74.
Merks P, Swieczkowski D, Byliniak M, Drozd M, Krupa K, Jaguszewski M, Brindley DA, Naughton BD. The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists. Eur J Hosp Pharm Sci Pract. 2018, 25(1), 10-15. DOI: https://doi.org/10.1136/ejhpharm-2016-000970
Policjanci CBŚP zlikwidowali największą na świecie nielegalną fabrykę podrabianych anabolików i leków na potencję; http://www.policja.pl/pol/aktualnosci/132049,Policjanci-CBSPzlikwidowali-najwieksza-na-swiecie-nielegalna-fabrykepodrabiany.html.
Narodowy Instytut Leków, Sfałszowane leki, Internet: http://www.nil.gov.pl/lekisfalszowane/.
POLICJA.PL; Zatrzymana za nielegalny handel lekami; Internet: http://www.policja.pl/pol/aktualnosci/157908,Zatrzymana-zanielegalny-handel-lekami.html.
CENTRALNE BIURO ŚLEDCZE POLICJI; Potężny cios CBŚP w rynek nielegalnych sterydów; Internet: http://www.cbsp.policja.pl/cbs/aktualnosci/161574,Potezny-cios-CBSP-w-rynek-nielegalnychsterydow.html.
Zarządzenie Ministra Zdrowia z dnia 9 września 2010 w sprawie powołania Zespołu do Spraw Fałszowania i Nielegalnego Obrotu Produktami Leczniczymi oraz Innymi Sfałszowanymi Produktami Spełniającymi Kryteria Produktu Leczniczego Dz. Urz.MZ z 2007 r., Nr 17, poz. 92.
WHO, Medical Product Alert N° 1/2018, Internet: https://www.who.int/medicines/publications/drugalerts/drug_alert1-2018/en/.
Gazetapolicja.pl, Viagra z gipsu, Internet: http://gazeta.policja.pl/997/archiwum-1/2018/numer-163-102018/165515,Viagra-z-gipsu.html.
Pharmaceutical Security Institute, P.S.I., Counterfeit Situation. PSI report, 2018. Internet: http://www.psi-inc.org/.
Degardin K, Jamet M, Guillemain A, Mohn T. Authentication of pharmaceutical vials. Talanta. 2019, 198, 487-500. DOI: https://doi.org/10.1016/j.talanta.2019.01.121
Fijałek Z, Sarna K. Wybrane aspekty jakości produktów leczniczych i suplementów diety – produkty substandardowe, nielegalne i sfałszowane. Rynek Farmaceutyczny. 2009, 7, 467-475.
Streit R. The Herceptin(R) case : A case of falsification of medicinal products to a greater extent. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017, 60(11), 1203-1207. DOI: https://doi.org/10.1007/s00103-017-2622-x
K Eben. Drug theft goes big, Internet: http://fortune.com/2011/03/31/drug-theft-goes-big/.
Art. 124b., Ustawa z dnia 6 września 2001 r. - Prawo farmaceutyczne, Dz.U.2019.0.499.
Rahman MS, Yoshida N, Tsuboi H, Tomizu N, Endo J, Miyu O, Akimoto Y, Kimura K. The health consequences of falsified medicines- A study of the published literature. Trop Med Int Health. 2018, 23(12), 1294-1303. DOI: https://doi.org/10.1111/tmi.13161
WHO, Alert N° 1/2015: Artemether Lumefantrine, Internet: https://www.who.int/medicines/publications/drugalerts/en/.
WHO, World malaria report 2017. Internet: https://www.who.int/malaria/publications/world-malaria-report2017/en/.
WHO. Malaria in children under five. Geneva: World Health Organization, 2018 Internet: http://www.who.int/malaria/areas/high_risk_groups/children/en/.
Maitland K. Severe Malaria in African Children - The Need for Continuing Investment. N Engl J Med. 2016, 375(25), 2416-2417. DOI: https://doi.org/10.1056/NEJMp1613528
Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J. 2019, 18(1), 5. DOI: https://doi.org/10.1186/s12936-018-2628-3
Elder DP, Kuentz M, Holm R. Antibiotic Resistance: The Need For a Global Strategy. J Pharm Sci. 2016, 105(8), 2278-2287. DOI: https://doi.org/10.1016/j.xphs.2016.06.002
Venhuis BJ, Oostlander AE, Giorgio DD, Mosimann R, du Plessis I. Oncology drugs in the crosshairs of pharmaceutical crime. Lancet Oncol. 2018, 19(4), e209-e217. DOI: https://doi.org/10.1016/S1470-2045(18)30101-3
Lee JH, Park HN, Park OR, Kim NS, Park SK, Kang H. Screening of illegal sexual enhancement supplements and counterfeit drugs sold in the online and offline markets between 2014 and 2017. Forensic Sci Int. 2019, 298, 10-19. DOI: https://doi.org/10.1016/j.forsciint.2019.02.014
Kuramoto N, Yabe D, Kurose T, Seino Y. A case of hypoglycemia due to illegitimate sexual enhancement medication. Diabetes Res Clin Pract. 2015, 108(1), e08-e10. DOI: https://doi.org/10.1016/j.diabres.2015.02.014
Janvier S, De Spiegeleer B, Vanhee C, Deconinck E. Falsification of biotechnology drugs: current dangers and/or future disasters? J Pharm Biomed Anal. 2018, 161, 175-191. DOI: https://doi.org/10.1016/j.jpba.2018.08.037
PEW, After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, Internet: https://www.pewtrusts.org/en/research-and-analysis/reports/2011/07/12/after-heparin-protecting-consumers-from-the-risks-of-substandard-and-counterfeit-drugs.
INFARMA, Jak powstają leki, Internet: https://www.infarma.pl/innowacje/jak-powstaja-leki/.
Levinson M. U.S. manufacturing in international perspective. Congressional Research Service. February 20, 2014. Internet: www.fas.org/sgp/crs/misc/R42135.pdf.
Wajsman N, Burgos CA, Davies Ch. THE ECONOMIC COST OF IPR INFRINGEMENT IN THE PHARMACEUTICAL INDUSTRY, EUPIO, 2016, Internet: https://euipo.europa.eu/tunnel-web/secure/webdav/guest/document_library/observatory/resources/research-andstudies/ip_infringement/study9/pharmaceutical_sector_en.pdf.
Blackstone EA, Fuhr JP, Jr., Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits. 2014, 7(4), 216-224.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.